Publications by authors named "S Matrat"

Objectives: Resistance to fluoroquinolones (FQs) in Mycobacterium tuberculosis (Mtb) is mainly due to mutations in DNA gyrase (GyrA2B2), with the most common substitutions located at positions 90 and 94 in GyrA. Two clinical MDR Mtb (MDR-TB) strains harbouring an A90E or D94N substitution in GyrA were found to be surprisingly susceptible to FQs (ofloxacin MIC ≤2 mg/L). We studied the impact of the additional GyrA substitutions found in these strains (T80A and T80A + A90G, respectively) on FQ susceptibility.

View Article and Find Full Text PDF

Expression of genes of the locus of enterocyte effacement (LEE) is essential for adherence of enterohemorrhagic Escherichia coli (EHEC) to intestinal epithelial cells. Gut factors that may modulate LEE gene expression may therefore influence the outcome of the infection. Because nitric oxide (NO) is a critical effector of the intestinal immune response that may induce transcriptional regulation in enterobacteria, we investigated its influence on LEE expression in EHEC O157:H7.

View Article and Find Full Text PDF

Seven Klebsiella pneumoniae isolates from dogs and cats in Spain were found to be highly resistant to aminoglycosides, and ArmA methyltransferase was responsible for this phenotype. All isolates were typed by multilocus sequence typing (MLST) as ST11, a human epidemic clone reported worldwide and associated with, among others, OXA-48 and NDM carbapenemases. In the seven strains, armA was borne by an IncR plasmid, pB1025, of 50 kb.

View Article and Find Full Text PDF
Article Synopsis
  • The main mechanism of fluoroquinolone resistance in Mycobacterium tuberculosis is linked to mutations in the DNA gyrase protein, particularly in the gyrA gene, though unknown mutations in the gyrB gene are also being found more frequently.
  • Researchers studied the effects of eight specific gyrB mutations on fluoroquinolone susceptibility and found that these mutations, even in FQ-resistant strains, do not contribute to resistance.
  • The study emphasizes that testing DNA gyrase inhibition is crucial for understanding the role of mutations in fluoroquinolone resistance, suggesting that the presence of gyrB mutations should not automatically exclude the use of fluoroquinolones in TB treatment.
View Article and Find Full Text PDF

Mycobacterium tuberculosis DNA gyrase, a nanomachine that is involved in the regulation of DNA topology, is the only type II topoisomerase present in this organism and hence is the sole target for fluoroquinolone action. The breakage-reunion domain of the A subunit plays an essential role in DNA binding during the catalytic cycle. Two constructs of 53 and 57 kDa (termed GA53BK and GA57BK) corresponding to this domain have been overproduced, purified and crystallized.

View Article and Find Full Text PDF